These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18992294)

  • 21. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
    Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
    Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
    Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
    J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer.
    Vandermeulen G; Athanasopoulos T; Trundley A; Foster K; Préat V; Yáñez-Muñoz RJ; Dickson G
    J Control Release; 2012 May; 159(3):376-83. PubMed ID: 22310089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
    Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
    Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
    Wingard JB; Anderson B; Weissman D
    Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant.
    Sun J; Hou J; Li D; Liu Y; Hu N; Hao Y; Fu J; Hu Y; Shao Y
    Vaccine; 2013 Jan; 31(3):472-9. PubMed ID: 23174201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine.
    Bråve A; Ljungberg K; Boberg A; Rollman E; Engström G; Hinkula J; Wahren B
    Vaccine; 2006 May; 24(21):4524-6. PubMed ID: 16174543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.
    Deshmukh TM; Lole KS; Tripathy AS; Arankalle VA
    Vaccine; 2007 May; 25(22):4350-60. PubMed ID: 17459540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
    Boberg A; Gaunitz S; Bråve A; Wahren B; Carlin N
    Vaccine; 2008 Sep; 26(40):5079-82. PubMed ID: 18514370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.
    Verstrepen BE; Bins AD; Rollier CS; Mooij P; Koopman G; Sheppard NC; Sattentau Q; Wagner R; Wolf H; Schumacher TN; Heeney JL; Haanen JB
    Vaccine; 2008 Jun; 26(26):3346-51. PubMed ID: 18467010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
    Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
    Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
    Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
    Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.